Frederic Perry
3 Papers
29 Citations
Frederic Perry is an academic researcher. The author has contributed to research in topics: Regimen & Maintenance therapy. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial
Noel-Jean Milpied,Steven Legouill,Thierry Lamy,Vincent Delwail,Remy Gressin,Denis Guyotat,Gandhi Damaj,Charles Foussard,Philippe Quittet,Hervé Maisonneuve,Eric Deconinck,François Dreyfus,Emmanuel Gyan,Laurent Sutton,Nadine Morineau,Magda Alexis,Frederic Perry,Mathieu Sauvezie +17 more
TL;DR: The preliminary analysis of a multicenter randomized trial aiming at comparing the results of R- CHOP every 14 days to R- HDT in adults with untreated confirmed DLBCL and the main objective of the study was the EFS with an event defined as insufficient intermediate response, progression, relapse or death.
20
Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial
Arnaud Pigneux,Chantal Himberlin,Mathilde Hunault-Berger,Francis Witz,Christian Recher,Jean-Luc Harousseau,Olivier Tournilhac,Christian Berthou,Martine Escoffre-Barbe,Denis Guyotat,Nathalie Fegueux,Martine Delain,Bruno Lioure,Eric Jourdan,Didier Bouscary,Laurence Legros,Noel Milpied,Frédéric Bauduer,Frederic Perry,Isabelle Luquet,Marie-Christine Béné,Norbert Ifrah,Jean-Jacques Sotto,Philippe Guardiola +23 more
TL;DR: The French group, GOELAMS, performed a multicenter phase III randomized open trial to evaluate whether adding androgens to post-remission induction therapy was associated with an improved outcome in elderly pts with de novo AML; especially in those achieving CR and remaining in remission for at least a year.
7
A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study.
Arnaud Pigneux,Chantal Himberlin,Mathilde Hunault-Berger,Francis Witz,Christian Recher,Jean-Luc Harousseau,Olivier Tournilhac,Chistian Berthou,Martine Escoffre-Barbe,Denis Guyotat,Nathalie Fegueux,Martine Delain,Bruno Lioure,Frédéric Bauduer,Eric Jourdan,Didier Bouscary,Laurence Legros,Frederic Perry,Noel-Jean Milpied,Marie-Christine Béné,Norbert Ifrah,Jean-Jacques Sotto +21 more
TL;DR: In conclusion, the ICL regimen followed by six reinductions and two years maintenance therapy induce high CR rates and improve OS and DFS, however the addition of androgens did not decrease the relapse rate.
2